Clinical Trial Update: Liposomal Lurtotecan in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer [Phase 2]

View source ↗

Summary

This document reports on a completed Phase 2 trial evaluating liposomal lurtotecan in patients with metastatic or locally recurrent head and neck cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• liposomal lurtotecan (lurtotecan)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Head and Neck Cancer | Phase 2 | Status: COMPLETED